Airway Vista 2022

About Boehringer Ingelheim

Boehringer is one of the top leading global company founded in Germany in 1885.
Boehringer Ingelheim Korea is a Korean subsidiary of the Boehringer Ingelheim group. It was founded in 1976 in Korea We concentrate on developing innovative therapies in respiratory, oncology, diabetes, cardiovascular disease, animal health that can extend patient’ live.

About VAHELVA® (COPD)

VAHELVA® RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray is a prescription medicine used long term, 2 puffs 1 time each day, in controlling symptoms in adults with chronic obstructive pulmonary disease (COPD). COPD is a chronic lung disease that includes chronic bronchitis, emphysema, or both.

TOviTO® is Boehringer Ingelheim’s Phase IV clinical trial program assessing the safety and efficacy of VAHELVA® RESPIMAT®(tiotropium/olodaterol) in COPD. VAHELVA® RESPIMAT® can do more to improve lung function, dyspnea, exercise endurance and QoL compared to its monotherapy treatment components.

Many patients with suboptimal peak inspiratory flow (sPIF) cannot achieve a PIF adequate to inhale optimally from a DPI. VAHELVA® RESPIMAT® actively delivers soft mist, independent of patients’ ability to inhale. Slow moving, long-lasting soft mist helps to provide lung deposition.